Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone

Table 1

Summary of clinical data of patients under study.

Patient no./sex/age, yrs	Type of MS	Time since initial symptoms, yrs	Time since diagnosis, yrs	MS therapy in previous 5 yrs	EDSS at baseline	Relapses in previous 2 yrs	MRI findings; (within 6 months before treatment); T2/T1/T1Gd	OCB
1/F/25	RR	3	1	None	3.0	3	34/22/5	+
2/F/21	RR	3	2	None	2.0	2	48/9/3	+
3/F/26	SP	4	3	INFβ-1b 250 μg	6.0	4	35/11/3	+
4/M/23	RR	2	2	INFβ-1a 30 μg	3.0	3	24/8/2	+
5/F/25	RR	2	2	INFβ-1b 250 μg	4.0	3	53/18/3	+
6/M/38	PP	12	10	GA; Auto-HSCT	6.0	4	38/20/0	+
7/F/42	RR	6	6	Auto-HSCT	2.0	1	38/15/5	−
8/M/28	SP	10	10	INFβ-1b 250 μg	7.5	4	31/12/10	+
9/F/35	SP	12	10	Auto-HSCT	6.0	1	38/23/0	+
10/F/20	RR	2	2	INFβ-1b 250 μg	4.0	2	133/34/7	+
11/M/25	RR	3	3	None	4.5	4	23/6/4	+
12/F/28	RR	4	3	INFβ-1b 250 μg Mitoxantrone	5.0	4	24/7/8	+
13/M/50	RR	10	5	None	4.0	1	40/21/5	+
14/M/53	RR	1	0	GA	6.5	2	24/0/10	+
15/F/34	RR	6	4	GA	4.0	1	30/10/4	+
16/F/29	RR	4	2	None	6.0	3	27/8/4	+
17/M/29	RR	15	14	None	6.0	4	92/47/6	+
18/F/28	RR	3	2	INFβ-1b 250 μg	4.0	2	33/8/1	+
19/M/28	SP	4	2	None	6.0	3	24/8/9	+
20/M/30	SP	3	3	GA mitoxantrone	9.0	4	22/13/7	+
21/M/51	SP	12	10	INFβ-1b 250 μg	6.0	1	32/20/0	+
22/F/54	SP	13	10	GA mitoxantrone	6.5	3	28/19/6	+
23/M/24	RR	1	1	None	3.0	3	130/40/2	+
24/F/44	SP	6	5	None	6.0	2	36/3/1	+
25/M/23	RR			None	4.0	2	12/0/4	+
26/F/36	RR	4	4	None	6.0	3	4/1/4	+
27/F/40	RR	4	3	None	5.5	4	89/23/3	+
28/F/55	SP	3	3	Mitoxantrone	8.0	4	22/2/8	+

RR: relapsing-remitting; PP: primary progressive; SP: secondary progressive; INFβ: interferon beta; GA: glatiramer acetate; Auto-HSCT: autohematopoietic stem cells transplantation; T2(PD): hyperintense lesions; T1: hypointense lesions; T1Gd: gadolinium-enhanced lesions; OCB: oligoclonal bands.